Patients with chronic hepatitis B who achieved a subcirrhotic range of liver stiffness through antiviral therapy had a lower risk of hepatocellular carcinoma, according to a study in the Journal of Gastroenterology and Hepatology. Cancer risks were higher for patients in the cirrhotic range of liver stiffness value after two years of antiviral therapy, compared with those in the subcirrhotic range.
Subcirrhotic liver stiffness in hepatitis B reduces cancer risk
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.